Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer

Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.